These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 1673721)

  • 21. The role of anti-malarials in rheumatoid arthritis--the American experience.
    Khraishi MM; Singh G
    Lupus; 1996 Jun; 5 Suppl 1():S41-4. PubMed ID: 8803910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bronchoalveolar lavage and lung biopsy in rheumatoid arthritis. In vivo effects of disease modifying antirheumatic drugs.
    Scherak O; Popp W; Kolarz G; Wottawa A; Ritschka L; Braun O
    J Rheumatol; 1993 Jun; 20(6):944-9. PubMed ID: 8102405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors influencing length of time taking methotrexate in rheumatoid arthritis.
    Ortendahl M; Schettler JD; Fries JF
    J Rheumatol; 2000 May; 27(5):1139-47. PubMed ID: 10813279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease-modifying drugs for progressive rheumatoid arthritis.
    Bunch TW; O'Duffy JD
    Mayo Clin Proc; 1980 Mar; 55(3):161-79. PubMed ID: 6766523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
    Simon LS
    Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
    Wolfe F; Michaud K; Stephenson B; Doyle J
    J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine.
    Conaghan PG; Brooks P
    Curr Opin Rheumatol; 1996 May; 8(3):176-82. PubMed ID: 8796975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts.
    Wolfe F; Hawley DJ; Cathey MA
    J Rheumatol; 1990 Aug; 17(8):994-1002. PubMed ID: 1976811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drugs for rheumatoid arthritis.
    Med Lett Drugs Ther; 1991 Jul; 33(848):65-70. PubMed ID: 1676134
    [No Abstract]   [Full Text] [Related]  

  • 32. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
    Osiri M; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trials.
    Dahl SL; Samuelson CO; Williams HJ; Ward JR; Karg M
    Pharmacotherapy; 1990; 10(2):79-84. PubMed ID: 2112243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine, and levamisole.
    Husain Z; Runge LA
    J Rheumatol; 1980; 7(6):825-30. PubMed ID: 6451692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
    Matteson EL; Weyand CM; Fulbright JW; Christianson TJ; McClelland RL; Goronzy JJ
    Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The methotrexate therapeutic response in rheumatoid arthritis.
    Ortendahl M; Holmes T; Schettler JD; Fries JF
    J Rheumatol; 2002 Oct; 29(10):2084-91. PubMed ID: 12375316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy.
    Fries JF; Williams CA; Singh G; Ramey DR
    J Rheumatol; 1997 May; 24(5):838-44. PubMed ID: 9150069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relative toxicity of disease-modifying antirheumatic drugs.
    Fries JF; Williams CA; Ramey D; Bloch DA
    Arthritis Rheum; 1993 Mar; 36(3):297-306. PubMed ID: 8452574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists.
    Criswell LA; Such CL; Yelin EH
    J Rheumatol; 1997 Dec; 24(12):2283-90. PubMed ID: 9415629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.